Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer

Recruiting now · Not applicable

Conditions studied: Squamous Cell Cancer of Head and Neck (SCCHN)

In brief

This is a randomized, single centre, single blinded prospective study comparing the standard of care imaging guided radiation therapy and daily adaptive radiotherapy (ART) for submandibular gland-sparing in head and neck cancer

Key facts

Study ID

NCT07348887

Run by

University Health Network, Toronto

People needed

50

Starts

2025-10-15

Expected to finish

2029-10-01

Last updated by the study team

2026-03-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Histologically proven Squamous Cell carcinoma of head and neck
• Bilateral neck being treated
• At least one level 1b not being treated electively and with no target structure, other than elective level II/III, <1cm to spared SMG
• ECOG PS 0-2
• Planned for curative (chemo)radiotherapy
• Able to receive and understand verbal and written information regarding study and able to give written informed consent
• Be able to lie comfortably on back and to wear immobilization for up to 1 hour

You may not qualify if…

• As judged by investigator evidence of systemic disease that makes unsuitable for study
• Pregnancy
• Underlying salivary dysfunction prior to treatment judged by investigator to affect likelihood of benefit from ART

Where it is running

• Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.